Tolimidone

Tolimidone (CP-26154; MLR-1023) is a compound which was discovered by scientists at Pfizer, was found to stimulate secretion of gastric mucosa, and was in development by Pfizer as a drug candidate to treat gastric ulcers but was abandoned.^[1][2][3][4] After the patent on the compound expired, scientists at the company Melior Discovery identified it as a potential drug candidate for diabetes through a phenotypic screen.^[4] The company proceeded to show that MLR-1023 is an allosteric activator of Lyn kinase with an EC50 of 63 nM.^[5][6] As of 2012 Melior was repurposing it for diabetes.^[1][7] In June 2016, the company reported positive results from their Phase 2a clinical study in diabetic subjects^[8][9]

Tolimidone

Clinical data
Other names	CP-26154, MLR-1023
Identifiers
IUPAC name 5-(3-methylphenoxy)pyrimidin-2(1H)-one
CAS Number	41964-07-2
PubChem CID	39065
ChemSpider	35751
UNII	MU3JD8E9IS
KEGG	D06182
ChEMBL	ChEMBL8030
CompTox Dashboard (EPA)	DTXSID50194786
ECHA InfoCard	100.230.742
Chemical and physical data
Formula	C11H10N2O2
Molar mass	202.213 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C2/N=C\C(\Oc1cc(ccc1)C)=C/N2